Skip to content
Screener

Avalo Therapeutics AVTX Q3 2025 earnings

Reported November 6, 2025 · Before market open

Revenue-
EPS-$2.19Miss by $0.52
EPS estimate-$1.67

Next report

Nov 5, 2026 (in 2 months)
EPS estimate-$0.56

Financials

Q3 2025

Income statement

See full
Revenue--100%
Operating income-$19.2M-49.3%
Net income-$30.6M-233%
EPS (diluted)-$2.19+22.6%

Balance sheet

See full
Cash & equivalents$27.3M-66.8%
Total debt$555.0K-66.0%
Total equity$91.5M+334%
Total assets$125.1M+27.1%

Cash flow

See full
Operating cash flow-$16.4M-42.0%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$167.17M+81.4%
Enterprise value$140.46M+1,095%

Returns & leverage

See full
Return on equity-177.4%-267pp
Debt / equity0×-0.1×
Current ratio14.3×+12.9×

FAQ

When did Avalo Therapeutics report Q3 2025 earnings?
Avalo Therapeutics (AVTX) reported Q3 2025 earnings on November 6, 2025 before market open.
What were Avalo Therapeutics's Q3 2025 revenue and EPS?
Avalo Therapeutics reported revenue of - and eps of $-2.19 for Q3 2025.
Did Avalo Therapeutics beat estimates in Q3 2025?
EPS missed the consensus estimate of $-1.67 by $0.52.
How did Avalo Therapeutics's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 100.0% from $249.0K a year earlier and eps grew 22.6% from $-2.83.
Where can I find Avalo Therapeutics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001534120-25-000017) and the 10-Q periodic report (0001534120-25-000018) directly on SEC EDGAR. The filing index links above go to sec.gov.